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Thyroid hormone abnormalities are common in critically ill patients. For over three decades, a mild form of these abnormalities
has been described in patients with several diseases under outpatient care.These alterations in thyroid hormone economy are a part
of the nonthyroidal illness and keep an important relationship with prognosis in most cases. The main feature of this syndrome is
a fall in free triiodothyronine (T3) levels with normal thyrotropin (TSH). Free thyroxin (T4) and reverse T3 levels vary according
to the underlying disease. The importance of recognizing this condition in such patients is evident to physicians practicing in a
variety of specialties, especially general medicine, to avoid misdiagnosing the much more common primary thyroid dysfunctions
and indicating treatments that are often not beneficial. This review focuses on the most common chronic diseases already known
to present with alterations in serum thyroid hormone levels. A short review of the common pathophysiology of the nonthyroidal
illness is followed by the clinical and laboratorial presentation in each condition. Finally, a clinical case vignette and a brief summary
on the evidence about treatment of the nonthyroidal illness and on the future research topics to be addressed are presented.
1. Introduction
The low T3 (triiodothyronine) syndrome, also known as
the euthyroid sick syndrome or the nonthyroidal illness
syndrome (NTIS), was initially described in the 1970s. It
represents a state of alterations in thyroid hormone (TH)
economy classically present in critically ill patients, particu-
larly those admitted to intensive care units [1]. These abnor-
malities are, by definition, not related to intrinsic diseases of
the hypothalamus-pituitary-thyroid axis but rather represent
imbalances in thyroid hormone production,metabolism, and
action [2].
The hallmark of this syndrome is a fall in serum T3
levels that may be accompanied by a drop in serum thyroxine
(T4) levels. Serum thyrotropin (TSH) is usually normal but
may be slightly increased or even decreased. In the recent
decades, the syndrome has also been described in patients
with chronic conditions and under outpatient care [3–8].The
importance of recognizing this condition in such patients is
evident to physicians practicing in a variety of specialties,
especially general medicine, in order to avoid misdiagnosing
the much more common primary thyroid dysfunctions and
indicating treatments that are often not beneficial.
2. Laboratorial Presentation
Much information about the pathophysiology and the main
laboratorial abnormalities of NTIS is derived from animal
models or patients admitted to the intensive care unit. In
such patients, TH abnormalities usually show two distinct
temporal phases. In the first phase, acute modifications in
peripheral thyroid hormone metabolism predominate. In
the second phase, disturbances of neuroendocrine origin
predominate [9].
In patients under ambulatory care, the presentation often
carries components of both phases. The fall in T3 levels
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is always present and the diagnosis should be suspected
if low T3 presents concurrently with low or normal TSH.
There is often a rise in reverse T3 (rT3) levels as well,
and the decrease in T3/rT3 relationship is considered the
most sensitive parameter for diagnosis of NTIS [10]. This is
somewhat complicated in routine clinical care because rT3
is not part of thyroid hormone profiles. The value of free
T4 measurements in NTIS is a matter of debate; as results
are strongly influenced by the laboratorial method employed
[11]. The association between TH and prognosis is conserved
among various noncritical conditions [4, 12, 13]. The main
laboratorial abnormalities that may be identified in the most
common clinical situations associated with NTIS will be
discussed in the appropriate sections below.
3. Pathophysiology
In patients with noncritical diseases peripheral abnormalities
in hormone conversion predominate. The abnormalities are
better reflected by the relations T3/rT3 and FT3/rT3, cor-
roborating the action of peripheral mechanisms favouring
decreased thyroid hormone activation and increased inacti-
vation [14, 15].
The peripheral metabolism of TH is determined by the
action of the three selenodeiodinases (D1, D2, and D3)
that catalyse the interconversion of different iodothyronines.
Studies in critically ill patients have shown decreased activity
of D1 in liver and skeletal muscle [14], increasedD2 activity in
skeletal muscle [16], and increased activity of D3 in patients
with acute myocardial infarction [15]. The diminished pro-
duction of T3 from T4 resultant of low D1 activity combined
with increased rT3 production from increased D3 activity
generates the classical pattern of low T3 and increased rT3,
while also explainingwhy in some conditions higher T4 levels
may be found [17].
Additionally, abnormal production of thyroid binding
globulin (TBG) is a potential cause for thyroid hormone
alterations in patients with NTIS, especially if total T3 or
T4 is being measured. Usually, patients with NTIS have low
TBG levels [18]. In some cases, such as nephrotic syndrome,
massive protein loss can be a contributor for this [8]. Diseases
that affect the liver and patients with HIVmay show elevated
TBG levels that wouldmake the interpretation of laboratorial
data more difficult [19, 20]. The advent of free T3 measure-
ment almost eliminated this trouble since even conditions
with high TBG levels show low serum free T3 during NTIS
[21]. Patients treated with proinflammatory cytokines also
show decreased TBG levels, which are normalized after drug
interruption [22].
Proinflammatory cytokines are often elevated in NTIS
and have been demonstrated to correlate inversely with
thyroid hormone levels in the critically ill [23, 24] as well as
in patients with chronic diseases [4, 17, 25].
Furthermore, these cytokines are possibly implicated in
the suppression of hypothalamic-pituitary axis often seen
in NTIS [25]. Production of thyrotropin release hormone
(TRH) mRNA is decreased in patients with NTIS but not
in those who died of immediate external causes [26]. In-
creased pituitary activity of D2 has been demonstrated [16]
and may be a contributor for this abnormality [27]. More T3
produced locally by this enzyme could render the pituitary
euthyroid even in face of a generalized hypothyroid state,
with low circulating levels of T3 [27–29]. Since most chronic
ambulatory diseases carry a strong inflammatory component,
it is very likely that many (if not all) of these mechanisms
are present in these situations. The relationship between
proinflammatory cytokines and thyroid hormone levels has
been shown in patients with chronic obstructive pulmonary
diseases and diabetes mellitus [4, 17, 30].
An important factor that is worth mentioning is that
patients with chronic systemic diseases are often under
treatment with several drugs that can affect thyroid hormone
metabolism [31]. Among examples of situations where sys-
temic diseases that affect TH metabolism coexist with the
use of medications that also alter THmetabolism are patients
with heart or liver diseases taking beta-blockers [32, 33], those
with heart failure receiving amiodarone [34], and patients
with psychiatric conditions under treatment with lithium
and/or drugs that affect the hepaticmetabolismofTH [31, 35].
A discussion on this topic is beyond the scope of this review,
but this caveat should nonetheless be taken into account
when interpreting thyroid function tests in patients with
chronic conditions.
4. Nonthyroidal Illness in Different
Clinical Settings
NTIS has been reported in a variety of situations, even when
patients are well enough to be seen in an outpatient setting.
In this section, we review the most common conditions
associated with abnormalities in thyroid hormone levels that
are compatible with a mild or atypical form of NTIS. Table 1
summarizes the laboratorial abnormalities found in these
situations.
4.1. Caloric Deprivation. Changes in TH levels during pro-
longed fasting are linked to twomain factors: changes in basal
energy expenditure and leptin levels.
During caloric deprivation, the fall in serum T3 is be-
lieved to be an adaptative response directed to saving energy
and protein for enduring an acute stress stimulus [36]. It
results from peripheral inhibition of T4 metabolism and
decreased TSH response to hypothalamic TRH. It has been
shown that in a hypocaloric diet a fall in T3 levels occurs, with
a simultaneous transient increase in free T4 [37]. Increased
rT3 is observed in the first two weeks, followed by normaliza-
tion thereafter [38]. Normalization of rT3 levels occurred in
parallel to decreasedT3 concentrations [39, 40].The elevation
in serum rT3 levels is related to decreased catabolism by
deiodinases and not increased production from T4 [37].
The fall in T3 is a result of decreased conversion from T4.
Decreased ATP availability during fasting could impair T4
uptake by the liver as well as peripheral deiodination. Total
and free T4 are within normal concentrations [41].
More recent evidence shows that, in addition to a de-
creased conversion of T4 to T3 during fasting, suppression of
the hypothalamic-pituitary-thyroid axis is seen [40, 42, 43].
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Table 1: Summary of thyroid hormone abnormalities found in noncritically ill patients.
Total T3 Free T3 Reverse T3 Total T4 Free T4 TSH
Caloric deprivation ↓ ↓ ↑ ↓ ⇔ ⇔ or ↓
Heart failure ↓ ↓ ⇔ or ↑ ⇔ or ↓ ⇔ ⇔ or ↓
HIV infection ⇔ ⇔ or ↓ ⇔ or ↓ ⇔ ⇔ or ↓ ⇔
Renal diseases ↓ ⇔ ⇔ ⇔ or ↓ ⇔ or ↑ ⇔
Liver diseases ⇔ or ↑ ↓ ⇔ or ↑ ↑ ⇔ or ↓ ⇔
Pulmonary diseases ⇔ ↓ ⇔ or ↑ ⇔ ⇔ ⇔
Diabetes mellitus ↓ ↓ ⇔ or ↑ ↓ ⇔ or ↑ ⇔
Psychiatric illnesses ↑ ⇔ or ↑ ⇔ ↑ ⇔ or ↑ ↑
⇔: normal.
↑: increased.
↓: decreased.
Leptin is an important factor in this regard, because its
levels fall in concert with weight loss [44–46]. Leptin was
shown to stimulate TSH secretion, and this finding may help
to explain the increased TSH levels often found in obese
individuals [45, 46]. Patients who have a defective leptin
receptor due to genetic mutations show reduced pituitary
hormone secretion, with delayed puberty and diminished
TSH secretion [47]. Prevention of the starvation-mediated
fall in leptin levels by administration of exogenous leptin can
significantly blunt the abnormalities found in TH levels in
this situation [45]. It appears that in humans, as opposed to
what is seen in animalmodels, aminimal serum level of leptin
is necessary for adequate pituitary function andmaintenance
of leptin above this threshold prevents the fall in thyroid
hormone levels as well as other hormonal axes commonly
seen during prolonged fasting [46]. On the other hand, some
recent animal models of NTIS have shown that intrahepatic
D3 activity is increased independently of autonomic nerve
function [48].
4.2. HIV Infection. HIV infection and NTIS are related not
only by the chronic infection status, but also by the catabolic
state resulting from the disease itself and its opportunistic
infections [49–51]. A fall in serum T3 levels is found in
up to 20% of patients carrying the virus and 50% of those
harbouring an opportunistic infection [20, 50, 52]. Some
particularities are distinctive of this group of patients. Lower
T3 levels concomitant with high TBG levels are often seen in
this population [53]. Additionally, TBG levels increase as the
disease progresses, but patients with poor prognosis usually
have unchanged levels [54]. Another interesting finding,
characteristic of this population, is low rT3 levels [55]. The
low rT3 usually rises to normal levels upon hospitalization
due to opportunistic infections [52].
There are several pitfalls other than NTIS that can coexist
in a patient with HIV infection when analysing the results
of thyroid function tests, such as thyroid infiltration by
opportunistic pathogens (e.g., P. jirovecii), weight loss, med-
ications, and immune reconstitution syndrome [20, 52]. The
prevalence of antithyroid antibodies, although low, increases
after treatment and the consequent immune reconstitution
and may be a potential confounder [56]. Thyroid function
abnormalities are more frequent in patients under highly
active antiretroviral therapy (HAART). The most common
abnormality is subclinical hypothyroidism and FT4 is lower
when compared to control subjects. In one study, HAART
and particularly the use of stavudine were associated with
subclinical hypothyroidism [56].
Weight loss is common in HIV patients and one study
found that the most malnourished patients presented the
lowest serumT3 [51]. Patients are as a rule clinically euthyroid
and abnormalities in thyroid hormone levels are probably a
reflection of disease severity [57].
4.3. Heart Diseases. Thyroid hormones are important modu-
lators of several cardiac functions such as heart rate, cardiac
output, systemic vascular resistance, and inotropism [58].
Abnormalities in thyroid hormone levels are frequently seen
in situations of cardiac ischemia and congestive heart failure
and after bypass surgery [59–61].
In cases of acute myocardial infarction, a fall in T3, T4,
and TSH levels and an increase in rT3 have been reported.
The relation rT3/TT3 is proportional to the severity of the
case [62]. The total and free forms of T3 are also low after
cardiac arrest caused by ischemia when compared to patients
with noncomplicated myocardial infarction. Furthermore,
patients who experienced more prolonged cardiac arrest
showed lower TT3 and FT3 levels than those with shorter
resuscitation time [62]. Additionally, thyroid function tests
normalize after two weeks in patients who fully recover
[62]. Oxidative stress probably plays a major role in the
pathophysiology of thyroid hormone abnormalities in acute
myocardial ischemia, as a small clinical trial demonstrated
the ability of an anti-inflammatory medication to prevent
NTIS in this setting [63].
In congestive heart failure, the prevalence of NTIS is
around 18% [60] but can be as high as 23% [64]. Patients
with higher severity scores usually developmore pronounced
abnormalities in thyroid function tests than those less symp-
tomatic. Low T3 concentrations were associated with higher
mortality rates in patients hospitalized for heart failure,
and serum free T3 concentrations were stronger predictors
of mortality than established risk factors such as LDL-
cholesterol, age, and left ventricular ejection fraction. T3
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levels correlated with the New York Heart Association clas-
sification system [12].
4.4. Kidney Diseases. Thekidney has an important role in the
metabolism and excretion of thyroid hormones. Therefore, it
is not surprising that kidney diseases can cause abnormalities
in thyroid hormone axis [65].
In nephrotic syndrome, when proteinuria is greater than
3 g/24 hours with concomitant hypoalbuminemia, hyperc-
holesterolemia, and oedema, serum T3 concentrations are
low. Urinary loss of TBG, among other proteins, could jus-
tify such alterations. However, on patients with nephrotic
syndrome but preserved renal function, TBG concentrations
are within normal limits, falling only when there is impaired
renal function [8]. Reverse T3 is typically normal, contrasting
with other situations of NTIS when rT3 is often elevated [8].
Free T3 and T4 are usually normal and thyroid hormone
supplementation is reserved only for situations of increased
TSH, as a consequence of excessive urinary loss of thyroid
hormones, or if low T4 is present because of the use of high
dose corticosteroids for treatment of nephrotic syndrome [8].
In cases of terminal kidney disease, the almost complete
loss of renal filtration alters the hypothalamic-pituitary-
thyroid axis and causes abnormalities in peripheral thyroid
hormone metabolism [65]. Like other clinical situations
where NTIS occur, a decrease in T4 conversion to T3 with
resultant low serum T3 is seen [66]. Similarly to what is
observed in congestive heart failure, lower serum T3 levels
predictmortality in patients under haemodialysis [13]. Serum
rT3 levels are oftennormal, as in cases of nephrotic syndrome,
and conversion of T4 to rT3 is unchanged [8, 67]. Total
and free T4 are usually within reference ranges or mildly
decreased. Free T4 can be mildly elevated in situations of
heparin use to avoid blood clotting in the haemodialysis
machine [68]. Haemodialysis does not correct the thyroid
hormone imbalances of kidney failure, but this can be
achieved with renal transplantation [65, 69].
4.5. Liver Disease. Normal hepatic function is essential to
adequate metabolism of thyroid hormones. The liver is the
main organ responsible for conversion of T4 to T3 (by the
action of type 1 deiodinase), synthesis of TBG, T4 uptake,
and secondary release of T4 and T3 into the circulation.
Abnormalities in serum thyroid hormones are frequently
found in cases of cirrhosis, acute hepatitis, and chronic liver
disease [21, 70, 71].
In cases of cirrhosis, the most common finding is low
TT3 and FT3 concomitant to elevated rT3.The serum relation
TT3/rT3 is inversely associated with the severity of the
disease [72]. Free T4 may be increased, while TT4 can be
decreased due to low TBG and albumin synthesis. TSH is
usually normal or mildly increased, but the patients have a
euthyroid clinical presentation [21].
The alterations found in acute hepatitis are different from
other forms of liver disease. Elevated TBG is a consequence
of its hepatic release as an acute phase protein. Consequent-
ly, total T3 and T4 are usually elevated, while the free form
of thyroid hormones remains within normal range. A mild
elevation of rT3 can be found, while TSH is most often nor-
mal [19].
In chronic liver diseases thyroid hormone imbalances
resemble more those of acute hepatitis than the ones found
in liver cirrhosis. Examples of studied liver diseases are
primary biliary cirrhosis and autoimmune hepatitis. In these,
serum TBG levels are high, as are TT4 and TT3. However,
serum FT3 and FT4 are low [73]. Difficulties in hormone
assessments occur due to the fact that both conditions have an
autoimmune basis and exclusion of autoimmune thyroiditis is
warranted [7]. Noteworthily, thyroid hormone abnormalities
found in these diseases are not associatedwith prognosis [37].
4.6. Respiratory Diseases. Some authors have found evidence
of NTIS in chronic obstructive pulmonary disease. Karadag
et al. [4], in a study involving 83 patients in stable clinical
condition, 20 with acute exacerbations, and 30 healthy indi-
viduals, observed that patients with stable disease had FT3
levels 25% lower than healthy volunteers, without differences
in TSH or FT4. The fall in FT3 levels was associated with
increases in interleukin 6 and tumour necrosis factor alpha.
Acute exacerbations lead to further decreases in FT3 levels
and a small decrease in TSH levels, all of which returned to
basal levels after clinical stabilisation.
During tuberculosis infection, one study showed that
T3 levels are low in more than 50% of the patients, with
no change in TSH, T4, or serum TBG levels. After a short
period of treatment, T3 levels were restored to normality and
TBG levels rose to supernormal levels when compared to a
control group taking prophylactic treatment [74]. Although
this could have been attributed to drug induced hepatitis,
only one patient was diagnosed with the condition.
4.7. Diabetes Mellitus. Alterations of thyroid hormone axis
have been demonstrated in patients with diabetes mellitus
(DM). Some authors found decreased serum TT3 and, in a
few cases, TT4, concomitant to increased rT3 and low or
inappropriately normal TSH [75]. Comparable abnormalities
have been found in patients with type 1 DM, particularly in
the presence of poor glycaemic control, as reflected by higher
glycated haemoglobin levels [76–78]. Similar correlations
were found in patients with type 2 DM, especially when the
glycated haemoglobin was above 12% [75].
An interesting study conducted by Kabadi [3] in pa-
tients with recently diagnosed type 2 DM and glycated
haemoglobin above 10.8% found elevated rT3 and low T3
levels, but these abnormalities were fully reversed upon
restoration of good metabolic control.
As both type 2 DM and NTIS present a strong inflam-
matory pathogenesis, it is not surprising that subclinical
inflammation present in obesity and type 2 DM is correlated
with serum thyroid hormone levels. A recent work has shown
that rT3, waist circumference, and high-sensitivity C-reactive
protein were interrelated in patients with type 2 DM [17]. In
another study, a subset of patients with type 2 DM, serum
rT3 was elevated only in those with previous cardiovascular
disease, such as angina or stroke.These were also the patients
showing the greatest increase in hs-CRP levels [30]. In both
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studies, no relation between HbA1c and thyroid hormones
was found. Therefore, poor glycaemic control might not
be solely responsible for thyroid hormone abnormalities
in patients with DM. In fact, a recent study found that
abnormalities in FT4/rT3 and FT3/rT3 ratios in patients
with type 1 and type 2 diabetes were linked to higher serum
concentrations of proinflammatory markers associated with
NTIS, such as IL-6 [79], while HbA1c was related to higher
FT4/FT3 only in patients with type 1 diabetes. The data
suggests that in diabetesmellitus themain pathophysiological
process may be related to abnormal deiodinase activity.
Abnormalities in type 2 deiodinase have been related to a
higher incidence of type 2 diabetes [80] and increased insulin
resistance [81].
4.8. Psychiatric Illness. Abnormalities in thyroid hormone
profiles are not uncommon in patients with psychiatric
illnesses, especially if hospitalization is required. The main
disorders associated withNTIS in these patients are posttrau-
matic stress disorder, schizophrenia, and major depression
[82–84]. Psychiatric disorders are unique in that they present
high T3 and/or TSH levels, as opposed to the low thyroid
hormone and TSH levels found in other acute and chronic
diseases.
In posttraumatic stress disorder, patients may present
mild increases in serum total T3 levels but FT3, FT4, and
TSH are usually normal [82]. In those admitted due to
severe psychosis, about 1 in 10 will present thyroid function
abnormalities [83]. The most common is high T4 and TSH,
simulating the profile of patients with TSH-producing pitu-
itary tumours or resistance to thyroid hormone. Opposite to
what happens in the latter two conditions, thyroid hormones
and TSH usually normalize spontaneously in 7 to 10 days in
acute psychosis and a conservative approach is recommended
when evaluating such patients [85].
Patients with major depression may have TSH and T4
concentrations within the normal range, although showing
higher levels when compared to matched controls, as well as
low TRH-stimulated TSH levels [84]. These may be a result
of diminished TRH mRNA expression in the hypothalamus.
5. Treatment
Treatment of thyroid hormone abnormalities in patients with
NTIS is as controversial as its physiological interpretation.
Few clinical studies are available to assess thyroid hormone
replacement in this situation and almost all were conducted
in critically ill patients.
One study assessed the effects of replacement with
150mcg/day of thyroxine in four doses divided in 2 days in
patients with acute renal failure. The only difference encoun-
tered was in TSH levels and the treated group showed higher
mortality [86].
Of particular interest are the studies conducted in patients
with heart diseases subjected to coronary revasculariza-
tion, which showed increases in cardiac output and lesser
need for vasopressors during recovery but no other effects
[87]. Patients with advanced heart failure responded to
T3 administration with decreases in serum norepinephrine,
aldosterone, and atrial natriuretic peptide aswell as decreased
heart rate and improved left ventricular function without
major side effects [88]. It is noteworthy that treating systemic
inflammation can also prevent the abnormalities typical of
NTIS, as was demonstrated in a recent study in patients with
acute myocardial ischemia [63].
Thyroid hormone replacement in NTIS prevents the TSH
elevation that is expected in the recovery phase of the original
disease [89]. Since decreased conversion of T4 to T3 is present
in most cases of NTIS, some authors have advocated that if
treatment is warranted, it should include T3 or a combination
of T4 and T3 [90].
It is possible that treatment in acute situations where
decreased T3 is believed to be a proper adaptative response
to stressmay be harmful, while thyroid hormone replacement
in conditions of chronic low T3 may be beneficial, especially
in patients with heart diseases. However, it is noteworthy that
there are no randomized controlled clinical trials assessing
the effects of thyroid hormone supplementation in such
situations and treatment of these patients is therefore not
recommended.
6. Conclusion and Future Perspectives
Thyroid hormone abnormalities characterizing NTIS in dif-
ferent clinical setting are complex and have a multifactorial
origin.There is considerable variation in laboratorial presen-
tation, depending on the original disease. As is observed in
patients with acute and more severe diseases, the intensity
of thyroid hormone imbalances in patients with chronic
diseases represents the severity of the underlying disease
and keeps an intimate correlation with the prognosis in
most cases. Thyroid hormone replacement to such patients
is still largely debatable, as most studies were conducted in
patients with acute exacerbations. Patients with heart diseases
are most likely to benefit from such treatment, but this
should be confirmed in appropriately powered clinical trials.
Treatments targeting other aspects of NTIS such as systemic
inflammationmay show benefit in preventing the occurrence
of thyroid hormone abnormalities and also warrant further
research.
7. Clinical Case
A male patient, 61 years old, treated for congestive heart
failure since 2008 due to a myocardial infarction, had for the
last 6 months experienced progressive worsening of dyspnea
and lower limb oedema, despite frequent optimization of
his medication. Laboratorial investigation for his worsening
symptoms revealed a TSH of 4.3 IU/L (RV: 0.5–4.5 IU/L),
free T4 21 pmol/L (RV 10–23 pmol/L), and free T3 2.5 pmol/L
(RV 3.5–6.5 pmol/L). Echocardiography showed a dilated
heart, a left ventricle ejection fraction of 28%, and moderate
pulmonary hypertension. He was a smoker for 30 years
and had quit 10 years before. Other relevant comorbidities
included hypertension and hypercholesterolemia. His lipid
panel and ambulatory blood pressure profile were within
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targets. His clinician referred him for evaluation of a possible
hypothyroidism that could be contributing for the deteriora-
tion of cardiac function as well as evaluation for treatment.
Initial evaluation yielded negative antithyroid antibodies
and a magnetic resonance image of his pituitary revealed
no abnormalities. The low free T3 concomitant with normal
FT4 and TSH was interpreted as a form of NTIS in this
patient and as a marker of poor prognosis given the history
of heart failure and rapid progressing symptoms in the last
months. Treatment with T3 was considered, but as there is
no conclusive evidence that treatmentwith thyroid hormones
could improve the condition or even survival, it was decided
for observation and recommended for further investigation
into the cause of cardiac decompensation.
Coronary angiography revealed no new obstructions and
the patient had no signs or laboratorial evidence of infections.
Eventually, a computed tomography revealed a pulmonary
embolism as the cause for his worsening symptoms. The
patient was admitted for initiation of anticoagulant treatment
and showed progressive clinical improvement until discharge
7 days later. At the end of anticoagulant treatment, his dysp-
nea was back to previous levels and the echocardiography-
estimated right ventricle systolic pressure had improved.
A new thyroid function test was ordered and showed
TSH 4.1 IU/L; FT4 17 pmol/L; and FT3 3.1 pmol/L. Despite
the increase in serum FT3 after treatment of pulmonary
embolism, its levels remained below normal values, probably
due to the long term, irreversible heart failure.
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